Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Type 1 Diabetes Market Grown from 2024 to 2025?

In recent times, there has been a significant expansion of the type 1 diabetes market size. The anticipated growth is from $11.82 billion in 2024 to $13.62 billion in 2025, leading to a compound annual growth rate (CAGR) of 15.2%. The notable growth in the past can be linked to the increasing need for successful treatments, enhanced public understanding of type 1 diabetes, escalated funding for medication development, and the steady rise in healthcare spending globally.

What Growth Rate Is Anticipated for the Type 1 Diabetes Market in the Coming Years?

The market for type 1 diabetes is projected to experience swift expansion in the coming years. The market is forecasted to attain a value of $22.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.6%. The expected growth during the forecast period can be credited to the rising awareness about the importance of early diabetes diagnosis, the escalating acceptance of home-care environments, increased efforts to research advanced drugs and the heightened awareness for nutritious product consumption. The anticipated trends for the forecast period include cutting-edge insulin formulations, advancements in medications and interventions, the use of artificial pancreas systems, and tailored approaches to medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12872&type=smp

Who Are the Leading Companies in the Type 1 Diabetes Market?

Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Eli Lilly and Co Ltd., Novo Nordisk A/S, Vertex Pharmaceuticals Incorporated, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc., MannKind Corporation, Biocon Ltd., Virta Health Corp., Bigfoot Biomedical Inc., ViaCyte Inc., Beta Bionics Inc., Adocia SA, Senseonics Holdings Inc., Zealand Pharmaceuticals A/S, Sigilon Therapeutics Inc., Provention Bio Inc.

What Are the Key Drivers of the Type 1 Diabetes Market?

Government efforts aimed at addressing diabetes are anticipated to ignite the growth of the type 1 diabetes market in the future. Such efforts encompass policies, strategies, initiatives, or programs launched by a government or government body to tackle specific challenges, attain objectives or instigate beneficial shifts in various societal segments. Leading government bodies are rolling out numerous efforts to fight diabetes, inclusive of type 1 diabetes, curtailing the diabetes risk and ensuring all diabetes-diagnosed people can avail equal, comprehensive, cost-effective, and high-quality care and treatment. To exemplify, the government of Canada partnered with JDRF Canada in July 2023, a Canadian non-profit organization, investing $33 million to back 12 research endeavors aimed at prevention, detection, management, and treatment of diabetes. The provided funds will also aid a countrywide screening research consortium, amalgamating experts and individuals impacted by diabetes to boost early-stage, pre-symptomatic type 1 diabetes screening in Canada. Consequently, the escalating initiatives by the government to tackle diabetes are steering the growth of the type 1 diabetes market. Regarding the type 1 diabetes market surge, it is underpinned by the escalating obesity and heart disease rates. The surge in obesity and heart diseases are expected to drive the growth of the Type 1 Diabetes Market. Obesity denotes a medical disorder where excessive body fat has amassed to an unhealthy extent, whilst heart disease alludes to an assortment of conditions impairing the heart and blood vessels. Surplus body weight amplifies the risk of insulin resistance, leading to elevated blood sugar levels and the onset of type 1 diabetes, and high blood sugar levels can potentially harm blood vessels and nerves controlling the heart and blood vessels, causing heart disease. For instance, as per the Centers for Disease Control and Prevention (CDC), a US-based national public health body in September 2024, severe obesity prevalence among adults from August 2021 to August 2023 was 9.4%. This rate spiked particularly in the 20–39 age bracket at 9.5% and in the 40–59 age bracket at 12.0%, while merely 6.6% of adults aged 60 or more were labeled as critically obese. Meanwhile, data from the British Heart Foundation in September 2024 revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with roughly 4 million males and 3.6 million females having these conditions. These diseases account for approximately 27% of all UK deaths, which equals over 170,000 deaths each year, or around 480 deaths daily, symbolizing one death every three minutes. Hence, the growing obesity and heart disease rates are fueling the growth of the type 1 diabetes market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12872&type=smp

What Are the Key Market Segments in the Type 1 Diabetes Industry?

The type 1 diabetes market covered in this report is segmented –

1) By Product Type: Rapid Acting Insulin Analogs, Long-Acting Insulin Analogs, Premix Insulin Analogs, Others Product Types

2) By Device: Insulin Pump, Insulin Pen, Blood Glucose Meter

3) By Application: Childrens, Adults

4) By End-User: Hospital, Research Institutes, Home Care

Subsegments:

1) By Rapid Acting Insulin Analogs: Insulin Lispro, Insulin Aspart, Insulin Glulisine

2) By Long-Acting Insulin Analogs: Insulin Detemir, Insulin Glargine, Insulin Degludec

3) By Premix Insulin Analogs: Premixed Insulin Lispro, Premixed Insulin Aspart, Premixed Insulin Glargine

4) By Other Product Types: Insulin Pumps, Continuous Glucose Monitoring Systems, Non-Insulin Medications, Combination Therapies

What Are the Latest Trends in the Type 1 Diabetes Market?

Top corporations in the type 1 diabetes sector are striving for the creation of technologically superior solutions such as SmartGuard technology to maintain their market standing. SmartGuard technology is an innovative solution designed to assist individuals with diabetes who may have fears regarding hypoglycemia or lack awareness about it. For example, in March 2022, Medtronic PLC, a medical technology company based in Ireland, unveiled the MiniMed 780G system equipped with the latest SmartGuard technology. This novel product is a closed-loop insulin pump system set to streamline the management of type 1 diabetes. It automatically regulates the dispatch of basal insulin and correction boluses at five-minute intervals, facilitating diabetic patients to keep their glucose highs and lows under check more conveniently. Furthermore, this system allows patients to lessen variability and keep their glucose levels within predetermined limits, thus enabling a nearly normal lifestyle and superior clinical results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

What Are the Key Regional Markets in the Type 1 Diabetes Industry?

North America was the largest region in the type 1 diabetes market in 2024. The regions covered in type 1 diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12872

This Report Delivers Insight On:

1. How big is the type 1 diabetes market, and how is it changing globally?

2. Who are the major companies in the type 1 diabetes market, and how are they performing?

3. What are the key opportunities and risks in the type 1 diabetes market right now?

4. Which products or customer segments are growing the most in the type 1 diabetes market?

5. What factors are helping or slowing down the growth of the type 1 diabetes market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model